<p>Inhibrx Biosciences（納斯達克代碼：INBX - 獲取免費報告）於週四發佈了其財報。該公司報告本季度每股收益為（$2.28），超出分析師一致預期的（$2.94）$0.66，Zacks 報道。</p>
<p>獲取 <strong>Inhibrx Biosciences</strong> 的提醒：</p>
<h2>Inhibrx Biosciences 股價上漲 6.0%</h2>
<p>週五，Inhibrx Biosciences 股票上漲 $4.51，達到 $79.13。該公司的股票交易量為 600,093 股，而其平均交易量為 766,212 股。該股票的 50 日移動平均線為 $45.90，200 日移動平均線為 $27.91。Inhibrx Biosciences 的一年低點為 $10.81，一年高點為 $86.64。該股票的市值為 11.5 億美元，市盈率為 -7.48，貝塔係數為 1.09。該公司的債務與股本比率為 1.45，速動比率為 4.98，流動比率為 4.98。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家研究公司對 INBX 進行了評論。華爾街 Zen 在 8 月 17 日的報告中將 Inhibrx Biosciences 的股票評級從 “賣出” 上調至 “持有”。JMP Securities 在 8 月 22 日的研究報告中重申了對 Inhibrx Biosciences 股票的 “市場表現” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Inhibrx Biosciences 股票的 “賣出（d）” 評級。一位分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，Inhibrx Biosciences 當前的平均評級為 “減持”。</p>
<p><strong>閲讀我們對 INBX 的最新分析</strong></p>
<h2>Inhibrx Biosciences 的內部買賣</h2>
<p>在相關消息中，主要股東 Global Investors Lp Viking 於 10 月 7 日（星期二）出售了 350,000 股 Inhibrx Biosciences 股票。股票以平均價格 $32.25 出售，總交易額為 $11,287,500.00。交易後，內部人士在公司持有 67,018 股，價值約 $2,161,330.50。此次交易使其持股減少了 83.93%。該交易已在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。公司內部人士持有公司股票的 17.09%。</p>
<h2>Inhibrx Biosciences 的機構交易</h2>
<p>幾家機構投資者和對沖基金最近買賣了 INBX 的股票。Caligan Partners LP 在第三季度購買了 Inhibrx Biosciences 的新股份，價值約 $7,961,000。SummitTX Capital L.P. 在第三季度購買了 Inhibrx Biosciences 的新股份，價值約 $1,824,000。Bridgeway Capital Management LLC 在第二季度獲得了 Inhibrx Biosciences 的新頭寸，價值約 $235,000。Acuta Capital Partners LLC 在第三季度購買了 Inhibrx Biosciences 的新頭寸，價值約 $552,000。最後，Invesco Ltd. 在第二季度獲得了 Inhibrx Biosciences 的新股份，價值約 $193,000。機構投資者和對沖基金持有公司 82.46% 的股票。</p>
<h2>Inhibrx Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Inhibrx, Inc. 是一家臨牀階段的生物製藥公司，開發一系列新型生物治療候選藥物。該公司的治療候選藥物包括 INBRX-101，一種用於治療 AAT 缺乏症患者的 alpha-1 抗胰蛋白酶（AAT）-Fc 融合蛋白治療候選藥物，目前正在進行 1 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Inhibrx Biosciences</li>
<li>股票交易：RSI 及其用途</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>如果你等着抄底，Micron Technology 可能會讓你錯過</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Inhibrx Biosciences 嗎？</h2>
<p>在考慮 Inhibrx Biosciences 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Inhibrx Biosciences 並不在名單上。</p>
<p>雖然 Inhibrx Biosciences 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

INBX

<p>Inhibrx Biosciences（納斯達克代碼：INBX）公佈了季度財報，報告每股虧損 2.28 美元，優於市場普遍預期的 2.94 美元虧損。股價上漲 6.0%，至 79.13 美元。該公司的市值為 11.5 億美元，債務與股本比率為 1.45。分析師對該股票的評級褒貶不一。主要股東 Global Investors Lp Viking 出售了 350,000 股。機構投資者持有該公司 82.46% 的股份</p>

<p>Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) posted its earnings results on Thursday. The company reported ($2.28) EPS for the quarter, beating analysts' consensus estimates of ($2.94) by $0.66, Zacks reports.</p>
<div class="lb-trans"><p>Inhibrx Biosciences（納斯達克代碼：INBX - 獲取免費報告）於週四發佈了其財報。該公司報告本季度每股收益為（$2.28），超出分析師一致預期的（$2.94）$0.66，Zacks 報道。</p>
</div><p>Get <strong>Inhibrx Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Inhibrx Biosciences</strong> 的提醒：</p>
</div><h2>Inhibrx Biosciences Trading Up 6.0%</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 股價上漲 6.0%</h2>
</div><p>Inhibrx Biosciences stock traded up $4.51 during trading on Friday, hitting $79.13. The company's stock had a trading volume of 600,093 shares, compared to its average volume of 766,212. The stock's fifty day moving average is $45.90 and its 200 day moving average is $27.91. Inhibrx Biosciences has a 1-year low of $10.81 and a 1-year high of $86.64. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.48 and a beta of 1.09. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.98 and a current ratio of 4.98.</p>
<div class="lb-trans"><p>週五，Inhibrx Biosciences 股票上漲 $4.51，達到 $79.13。該公司的股票交易量為 600,093 股，而其平均交易量為 766,212 股。該股票的 50 日移動平均線為 $45.90，200 日移動平均線為 $27.91。Inhibrx Biosciences 的一年低點為 $10.81，一年高點為 $86.64。該股票的市值為 11.5 億美元，市盈率為 -7.48，貝塔係數為 1.09。該公司的債務與股本比率為 1.45，速動比率為 4.98，流動比率為 4.98。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research firms have commented on INBX. Wall Street Zen upgraded shares of Inhibrx Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, August 17th. JMP Securities reaffirmed a &#34;market perform&#34; rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Inhibrx Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Inhibrx Biosciences currently has an average rating of &#34;Reduce&#34;.</p>
<div class="lb-trans"><p>幾家研究公司對 INBX 進行了評論。華爾街 Zen 在 8 月 17 日的報告中將 Inhibrx Biosciences 的股票評級從 “賣出” 上調至 “持有”。JMP Securities 在 8 月 22 日的研究報告中重申了對 Inhibrx Biosciences 股票的 “市場表現” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Inhibrx Biosciences 股票的 “賣出（d）” 評級。一位分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，Inhibrx Biosciences 當前的平均評級為 “減持”。</p>
</div><p><strong>Read Our Latest Analysis on INBX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 INBX 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Inhibrx Biosciences</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 的內部買賣</h2>
</div><p>In related news, major shareholder Global Investors Lp Viking sold 350,000 shares of Inhibrx Biosciences stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $32.25, for a total transaction of $11,287,500.00. Following the transaction, the insider owned 67,018 shares in the company, valued at approximately $2,161,330.50. The trade was a 83.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 17.09% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，主要股東 Global Investors Lp Viking 於 10 月 7 日（星期二）出售了 350,000 股 Inhibrx Biosciences 股票。股票以平均價格 $32.25 出售，總交易額為 $11,287,500.00。交易後，內部人士在公司持有 67,018 股，價值約 $2,161,330.50。此次交易使其持股減少了 83.93%。該交易已在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。公司內部人士持有公司股票的 17.09%。</p>
</div><h2>Institutional Trading of Inhibrx Biosciences</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 的機構交易</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of INBX. Caligan Partners LP bought a new stake in shares of Inhibrx Biosciences in the 3rd quarter worth approximately $7,961,000. SummitTX Capital L.P. bought a new stake in Inhibrx Biosciences in the 3rd quarter valued at about $1,824,000. Bridgeway Capital Management LLC acquired a new position in Inhibrx Biosciences during the 2nd quarter valued at about $235,000. Acuta Capital Partners LLC bought a new position in Inhibrx Biosciences in the 3rd quarter worth about $552,000. Finally, Invesco Ltd. acquired a new stake in shares of Inhibrx Biosciences in the second quarter valued at approximately $193,000. Institutional investors and hedge funds own 82.46% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買賣了 INBX 的股票。Caligan Partners LP 在第三季度購買了 Inhibrx Biosciences 的新股份，價值約 $7,961,000。SummitTX Capital L.P. 在第三季度購買了 Inhibrx Biosciences 的新股份，價值約 $1,824,000。Bridgeway Capital Management LLC 在第二季度獲得了 Inhibrx Biosciences 的新頭寸，價值約 $235,000。Acuta Capital Partners LLC 在第三季度購買了 Inhibrx Biosciences 的新頭寸，價值約 $552,000。最後，Invesco Ltd. 在第二季度獲得了 Inhibrx Biosciences 的新股份，價值約 $193,000。機構投資者和對沖基金持有公司 82.46% 的股票。</p>
</div><h2>Inhibrx Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.</p>
<div class="lb-trans"><p>Inhibrx, Inc. 是一家臨牀階段的生物製藥公司，開發一系列新型生物治療候選藥物。該公司的治療候選藥物包括 INBRX-101，一種用於治療 AAT 缺乏症患者的 alpha-1 抗胰蛋白酶（AAT）-Fc 融合蛋白治療候選藥物，目前正在進行 1 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Inhibrx Biosciences</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Inhibrx Biosciences</li>
<li>股票交易：RSI 及其用途</li>
<li>這三隻被低估的科技巨頭準備反彈嗎？</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>如果你等着抄底，Micron Technology 可能會讓你錯過</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=INBX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inhibrx Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Inhibrx Biosciences 嗎？</h2>
</div><p>Before you consider Inhibrx Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Inhibrx Biosciences 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Inhibrx Biosciences 並不在名單上。</p>
</div><p>While Inhibrx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Inhibrx Biosciences 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Inhibrx Biosciences（NASDAQ:INBX）公佈財報結果